Threohydrobupropion

Threohydrobupropion.svg

Threohydrobupropion is a metabolite of the antidepressant and smoking cessation aid bupropion. It is formed in the body through the reduction of bupropion by the enzyme carbonyl reductase. Threohydrobupropion, along with other metabolites such as hydroxybupropion and erythrohydrobupropion, contributes to the pharmacological effects of bupropion.

Pharmacology

Threohydrobupropion is known to inhibit the reuptake of the neurotransmitters dopamine and norepinephrine, similar to its parent compound bupropion. This action is believed to contribute to its antidepressant and smoking cessation properties. However, the potency of threohydrobupropion in inhibiting dopamine and norepinephrine reuptake is lower compared to bupropion and hydroxybupropion.

Metabolism

Bupropion is metabolized in the liver by the enzyme cytochrome P450 2B6 (CYP2B6) to form hydroxybupropion. Further reduction of bupropion by carbonyl reductase leads to the formation of threohydrobupropion and erythrohydrobupropion. These metabolites are then excreted in the urine.

Clinical Significance

The presence of threohydrobupropion and other metabolites in the body can influence the overall efficacy and side effect profile of bupropion. Understanding the role of these metabolites is important for optimizing the therapeutic use of bupropion in treating depression and aiding in smoking cessation.

See Also

• Bupropion
• Hydroxybupropion
• Erythrohydrobupropion
• Dopamine
• Norepinephrine
• Cytochrome P450 2B6

External Links

-

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian